Various studies reported the upregulation of TPD52 expression in quite a few cancers, such as breast, prostate, and pancreatic cancer, Burkitt’s lymphoma, multiple myeloma, and melanoma (12). This evidence concerns the gene TPD52 and plasma cell myeloma.